KIF26B and lung cancer: Furthermore, KIF26B silencing led to the downregulation of vimentin and N-cadherin, upregulation of E-cadherin, and diminished Wnt/β-catenin pathway activity, implicating KIF26B as a positive regulator of EMT and Wnt/β-catenin signalling in lung cancer cells [204].